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Abstract
Cellular senescence represents the state of irreversible cell cycle arrest during cell 
division. Cellular senescence not only plays a role in diverse biological events such as 
embryogenesis, tissue regeneration and repair, ageing and tumour occurrence pre-
vention, but it is also involved in many cardiovascular, renal and liver diseases through 
the senescence-associated secretory phenotype (SASP). This review summarizes the 
molecular mechanisms underlying cellular senescence and its possible effects on a 
variety of renal diseases. We will also discuss the therapeutic approaches based on 
the regulation of senescent and SASP blockade, which is considered as a promising 
strategy for the management of renal diseases.
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1  | INTRODUC TION
Cellular senescence refers to an irreversible cell cycle arrest. 
Senescent cells exhibit a series of changes in cell morphology and 
epigenetics, including the changes in cell cyclins and increased ex-
pression of β-galactosidase1; although there is replicative exhaustion 
in senescent cells, these cells still have metabolic activity.1 The inhi-
bition of DNA replication and rupture of its double-strand are typical 
features of cellular senescence.2 There are many causes of cellular 
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senescence including genomic damage, activation of oncogenes and 
inflammation.3
Cellular senescence plays a critical role in normal embryonic de-
velopment in humans and animals and is involved in wound healing.4 
However, enhanced cellular senescence is also found in multiple or-
gans in the process of ageing or after injury, suggesting that there 
should be different effects of cellular senescence depending on the 
pathophysiological context.5 More importantly, cellular senescence 
has been verified as a fundamental cause for the development of 
many diseases, such as cardiovascular, liver and kidney diseases 
(Figure 2).4 Additional studies confirm that the number of senescent 
cells increases in multiple anatomical sites in the kidney during age-
ing and kidney diseases.5,6 Therefore, preventing cellular senescence 
may be a potentially important approach to inhibit the development 
of chronic kidney disease (CKD).7 In this review, we will focus on 
the mechanisms of cellular senescence and the relationship between 
senescence and renal diseases.
2  | GENER AL CONCEPT OF CELLUL AR 
SENESCENCE AND SENESCENCE-
A SSOCIATED SECRETORY PHENOT YPE
In 1961, cellular senescence was first described as a consequence 
of replicative exhaustion in cultured human fibroblasts.8 Senescent 
cells are alive but display typical features of an enlarged, flattened 
morphology, senescence-associated heterochromatin marks, ac-
cumulation of lipofuscin granules, expression of β-galactosidase 
and lack of mitogenic responses.1 Cellular senescence can be clas-
sified into two different types according to the presence or the 
absence of telomere shortening: replicative senescence caused 
by shortening of telomeres and premature senescence caused 
by other stress signals such as aberrant oncogene activation and 
genomic damage.9
An important characteristic of senescent cells is their production 
of a series of proteins named as the senescence-associated secre-
tory phenotype (SASP).10 Through the SASP, senescent cells can af-
fect surrounding cells by secreting various inflammatory cytokines, 
chemokines, growth factors and extracellular matrix remodelling 
factors such as interleukin 1α (IL-1α), interleukin 6 (IL-6), plasminogen 
activator inhibitor-1 (PAI-1), TGF-β, connective tissue growth factor 
(CTGF) and monocyte chemoattractant protein-1 (MCP-1).10,11 The 
expression of SASP genes is up-regulated during senescence, mainly 
via the actions of NF-κB and C/EBPβ.12 mTOR signalling is also es-
sential for NF-κB activation and the secretion of pro-inflammatory 
SASP genes.13 Although the SASP was initially thought to be similar 
in all senescent cells, the function and specific composition of SASP 
varies greatly with the different types of stressors, different cell 
types and environments.
Senescent cells can exert beneficial or harmful effects through 
SASP and significantly influence their local microenvironment. 
These SASP factors induce senescence of adjacent cells through 
a paracrine fashion and contribute to inflammation, which in turn 
helps to remove senescent cells,14 and facilitate tissue repair and re-
modelling. Some factors promote the tumour-suppressive function 
of cellular senescence due to their crucial role for the onset of stable 
cell cycle arrest.15 The benefit of SASP usually exists in a transient 
situation such as in acute wound-healing events. However, when se-
nescent cells exist permanently, they may induce serious problems 
with long-term harmful consequences due to the chronic secretion 
of SASP factors such as IL-1α and MCP-1. Meanwhile, the increased 
expression of cytokines and chemokines by senescent cells, such as 
IL-6 and MCP-1, can attract immune cells to improve tissue recov-
ery by secreting more SASP factors and removing harmful factors.16 
If tissue repair fails, the increased SASP factors may accelerate 
the process of senescence, ultimately leading to ageing-associated 
damage.
3  | THE MECHANISMS AND REL ATED 
PATHWAYS OF CELLUL AR SENESCENCE
3.1 | Oxidative stress and inflammation
Increasing evidence suggests that persistent DNA damage response 
triggers cellular senescence.17 Oxidative stress can induce DNA dam-
age, which is an important mechanism related to stress-induced cel-
lular senescence.17 Intracellular ROS comes from mitochondria, cell 
membranes and endoplasmic reticulum. For example, reduction in 
the nicotinamide-adenine dinucleotide-ubiquinone oxidases and dys-
function of the mitochondrial electron transport chain are the main 
sources of ROS.18 Highly reactive oxygen molecules may damage li-
pids, DNA and proteins. Furthermore, it has been shown that several 
signalling pathways can be activated by ROS, such as p53/p21 sig-
nalling and mitogen-activated protein kinase pathways, resulting in 
enhanced apoptosis, inflammation and stress-induced senescence.19 
For example, a study has shown that ROS caused telomere-associated 
genomic instability and senescence in mesenchymal stem cells.20
At the same time, persistent and chronic inflammation may in-
duce senescence, although activation of inflammatory responses is 
necessary to remove pathogens and mediate tissue repair. For ex-
ample, several pro-inflammatory cytokines, especially IL-6 and IL-8, 
are important mediators in the induction of premature senescence. 
Activation of these two cytokines and their receptors initiates se-
nescence, whereas inhibition of these cytokines blocks senes-
cence.21 Also, an intense inflammatory process, including innate 
and adaptive immune responses, has been shown to regulate kidney 
senescence.22
3.2 | Increased expression of cyclin-dependent 
kinase inhibitors
It is known that cellular senescence is tightly correlated with up-
regulation of cyclin-dependent kinase (CDKs) inhibitors. The INK4α/
ARF locus (the cyclin-dependent kinase inhibitor 2A (CDKN2A) gene) 
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encodes two different proteins, p16INK4a (hereafter referred as p16) 
and ARF, through an alternative splicing mechanism. The expres-
sion of p16 is primarily regulated by environmental stress-induced 
DNA damage,23 which is predominant in stress-induced premature 
senescence (SIPS). SIPS can be induced by many stress signals, in-
cluding radiation, oxidative stress, chemical toxicants, DNA damage, 
oncogenic mutation and nutrient deficiency.9 The stimuli-induced 
DNA damage response (DDR) is involved in the activation of p16/
phosphorylated retinoblastoma (pRb) pathway, especially in epithe-
lial cells.
The cell cycle inhibitor p16 binds to cyclin-dependent kinase 4 and 
6 (CDK4/6) complex and inhibits its activity, thereby resulting in de-
phosphorylation of pRb and suppression of G1 phase progression24 
(Figure 1). The p16/pRb pathway may be essential for the initiation and 
maintenance of senescence. In addition, the expression of p16 is often 
used to identify senescent cells due to the expression of p16 in most 
(though not all) senescent cells.25 Therefore, control of p16 expression 
may be a promising treatment to inhibit cellular senescence.
p53 and p21Waf1/Cip1 (hereafter referred as p21) are also CDK in-
hibitors. Phosphorylation of p53 and enhanced p21 expression are 
associated with the telomere shortening-induced senescence and SIPS. 
p21 can contribute to inhibition of various CDKs, especially CDK2, 
leading to cell cycle arrest and replicative senescence26 (Figure 1). In 
addition, ARF binds and sequesters the murine double minute 2 on-
cogene protein into the nucleoli, which leads to inhibition of p53 ubiq-
uitination and degradation, thus resulting in cell cycle arrest through 
p53/p21 signalling pathway (Figure 1). Evidence strongly suggests that 
p53/p21 signalling is involved in the initiation of cellular senescence, 
but p16pRb signalling is necessary to maintain cellular senescence.27
3.3 | Telomere shortening
Telomeres are highly conserved non-coding repetitive TTAGGG se-
quences of DNA. These specialized structures protect genetic mate-
rial from damage by preventing fusion or damage to the chromosome 
ends. Telomerase is an enzyme that maintains telomeres and sustains 
chromosomal stability. As there is no telomerase expression in most 
human cells, except in the cells with highly proliferative capacity (bone 
marrow, skin and germ cells),28 telomeres shorten progressively as cells 
F I G U R E  1   The mechanisms and related pathways of cellular senescence. A variety of stressors induce telomere shortening, increase 
ROS production, enhance inflammation and autophagy and decrease expression of SIRT1 and Klotho. Telomere shortening, ROS and 
inflammation usually lead to DNA damage that induces activation of p16/pRb and p53/p21 pathways. Activation of p16 and p21 leads to 
inhibition of cyclin-dependent kinase (CDK) complexes and retinoblastoma protein (Rb); thus, senescence is present. Lower expression of 
SIRT1 causes activation of p53 and induces senescence. Decreased expression of Klotho leads to reduced inhibitory effects on insulin/
insulin-like growth factor-1(IGF-1) signalling and Wnt/β-catenin signalling, resulting in cellular senescence. In addition, autophagy induces 
cellular senescence through targeting Δ133p53α or lamin B. ROS, reactive oxygen species; DDR, DNA damage response; MDM2, murine 
double minute 2
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divide. Telomere shortening causes genetic instability and cell apop-
tosis, and is the main trigger of replicative senescence.29 Replicative 
senescence is found in many kinds of cells such as fibroblast, keratino-
cytes, endothelial cells, lymphocytes, adrenocortical cells and chon-
drocytes.30 In multiple cells, telomeres shorten progressively with 
successive cell division. In addition to replicative senescence, cellular 
senescence induced by various harmful stimuli can also result in short-
ening of the telomeres.29 A persistent DDR is activated when telom-
eres shorten to a critical length, which leads to the down-regulation 
of genes involved in cell cycle progression and the up-regulation of 
growth suppressors such as p53 and p16 (Figure 1).
3.4 | Down-regulation of Klotho or Sirtuin 
1 expression
In 1997, Klotho was discovered as a transmembrane protein usu-
ally expressed in proximal and distal renal tubules, which was sub-
sequently identified as an anti-ageing factor and shown to exert 
inhibitory effects on insulin/insulin-like growth factor-1 signalling 
(Figure 1), oxygen free radicals and phosphate/calcium homoeo-
stasis.31 Multiple ageing-associated diseases develop in mice with 
genetic deficiency of Klotho, including osteoporosis, stroke and ar-
teriosclerosis. Conversely, mice with overexpression of Klotho gene 
exhibit longer lifespan.32 If Klotho is exogenously administered, 
the senescence of endothelial cell can be significantly reduced.33 
Interestingly, the levels of Klotho were significantly decreased in 
old patients (80-89 years) with CKD compared to patients with CKD 
at the age of 60-69; serum Klotho levels were inversely correlated 
with age, suggesting that Klotho may serve a biomarker of ageing 
progression.34
Sirtuin 1(SIRT1) is also recognized as a key modulator of age-
ing. SIRT1 can deacetylate histone as well as non-histone proteins 
such as FOXOs, p53 and NF-κB,35,36 thereby influencing several 
important signalling pathways associated with cellular stress, 
metabolism and longevity. It has been shown that SIRT1 can in-
hibit cellular senescence of endothelial cells.37 Down-regulation 
of SIRT1 in endothelial cells leads to premature senescence-like 
phenotype by enhancing acetylation of p53. On the contrary, in-
creased expression and activity of SIRT1 prevent cells from en-
tering into the state of senescence by inhibiting p53 activity.37 
Furthermore, it has been shown that inhibition of miR-570-3p in 
small airway epithelial cells from COPD patients restores SIRT1 
expression, leading to SIRT1-dependent inhibition of senescence 
markers and cellular rejuvenation.38
3.5 | Other mechanisms
Another possible mechanism involved in cellular senescence is 
autophagy. Autophagy is a key catabolic cellular process, which 
degrades damaged proteins as well as organelles. Autophagy 
often exerts protective effects under various stress conditions.39 
Recently, autophagy was considered as an effective mechanism in-
volved in the induction of cellular senescence.40 During senescence, 
autophagy is induced and activated, consequently facilitating the 
F I G U R E  2   A schematic view of the effects of cellular senescence in renal diseases. In renal diseases, various types of cells may 
experience senescence such as endothelial cells and renal tubular epithelial cells (RTECs). Although senescence may have protective effects 
in the development of autosomal dominant polycystic kidney disease (ADPKD), acute phase of acute kidney disease (AKI) and renal fibrosis, 
senescence can promote the progression of several renal diseases, including AKI, diabetic nephropathy, glomerulonephritis, renal fibrosis 
and dysfunction of transplant kidney
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process of senescence. In addition, the senescence phenotype could 
be delayed if autophagy is inhibited.41 Furthermore, autophagy can 
cause cellular senescence by targeting Δ133p53α, a p53 isoform 
that inhibit full-length p53, or contributing to nuclear lamina degra-
dation under various circumstances42,43(Figure 1).
Senescent cells have been shown to be resistant to apoptosis.44 
The BCL-2 protein family, including the anti-apoptotic proteins BCL-
2, BCL-W and BCL-XL, is essential for senescent cell resistance to 
apoptosis.45 Increased expression of BCL-W and BCL-XL is involved 
in senescent cell resistance to apoptosis, and inhibition of BCL-W and 
BCL-XL causes death of senescent cells. Furthermore, a small-molecule 
inhibitor targeting the BCL-2, BCL-W and BCL-XL proteins (ABT-737) 
contributed to apoptosis of senescent cells both in vivo and in vitro.45
In addition, Wnt/β-catenin signalling is involved in the patho-
genesis of cellular senescence (Figure 1). Wnt/β-catenin signal-
ling is a conserved signalling pathway in organ development that 
remains silent in normal adult kidneys.46 According to a recent 
study,47 Wnt/β-catenin signalling and renin-angiotensin system 
(RAS) activity were up-regulated in ageing kidneys. Moreover, 
inhibition of Wnt/β-catenin signalling significantly protected the 
normal structure and function of mitochondria, which reduced 
age-related renal fibrosis. At the same time, ectopic expression 
of Klotho, an antagonist of endogenous Wnt/β-catenin activity, 
eliminated renal fibrosis in d-lactose-induced accelerated ageing 
mouse model by alleviating cellular senescence and mitochondrial 
dysfunction.47
4  | MARKERS FOR DETEC TION OF 
SENESCENCE
Currently, it is difficult to find unique markers to identify and quan-
tify senescent cells, especially under in vivo conditions. Senescent 
cells are classically arrested at G1/S transition of the cell cycle trig-
gered by eroded telomeres in ageing cells, thus typically display a 
DNA content characteristic of the G1 phase and express distinct cell 
cycle inhibitors such as p16, p21 and p53.48 Subsequently, p21 has 
been shown to mediate permanent cell arrest in G2/M transition in-
duced by DNA damage through inhibiting mitotic CDK complexes 
and pRb phosphorylation.49 Assessment of these cell cycle inhibitor 
expression is very helpful for senescence evaluation.
In addition to aforementioned CDK inhibitors, other well-known 
phenotypic markers are also considered to be indicators of cellular 
senescence. The secretion of SASP factors and the mitochondrial 
dysfunction50 are consequences of senescence, which stabilize the 
senescent state and promote paracrine senescence of neighbour-
ing cells. Therefore, monitoring the alterations of mitochondrial dy-
namics and the secretome may be used to estimate senescent cell 
burden. Increased expression and activity of senescence-associated 
β-galactosidase (SA-β-gal, a lysosomal hydrolase) are commonly ap-
plied to identify senescent cells.51 Also, telomere shortening inducing 
replicative limits can also indirectly, but effectively, identify cellular 
senescence. Increased production of senescence-associated DNA 
damage foci (SADF) and senescence-associated heterochromatic 
foci (SAHF) in the nucleus are also regarded as senescence markers. 
SADFs contain important proteins for induction of senescence.52 
Overexpression of proteins related to SAHF formation can also in-
duce senescence and inhibit the expression of genes associated with 
proliferation.53 Another common senescence marker is γ-H2AX, 
which is produced by the phosphorylation of the histone H2AX. 
Additionally, senescent cells often demonstrate distinctive changes in 
nuclear morphology associated with loss of lamin B1 (Figure 1), which 
is also a senescence-associated biomarker.54 In fact, until now, there 
is no single marker can be used to entirely define cellular senescence. 
Therefore, aforementioned markers have been used together to de-
termine senescent cells in different disease and ageing contexts.
In addition, DcR2, a decoy receptor for tumour necrosis fac-
tor-related apoptosis-inducing ligand, is a marker of senescence.55 
Previous studies found that DcR2 is highly expressed in senescent 
tumour cells and senescent hepatic stellate cell.55 Recently, it has 
been shown that DcR2 is exclusively expressed in renal tubular ep-
ithelia and co-expressed with senescent markers in patients with 
diabetic nephropathy, and the extracellular portion of DcR2 is de-
tectable in urine.56
5  | SENESCENCE IN RENAL DISE A SES
5.1 | Type of renal senescent cells
During ageing and renal diseases, senescent cells can be observed 
in the cortex and medulla. Generally, proximal tubular cells in the 
cortex are the majority of senescent cells. They are predominant 
G2-arrested senescent cells.57 Although senescent cells are mainly 
present in tubular epithelial cells, other kinds of cells may become 
senescent. For example, increased p16 expression was described 
in the glomerular cells during glomerular diseases, such as glo-
merulonephritis, membranous nephropathy, diabetic nephropathy 
and focal segment glomerular sclerosis.58,59 In addition, vascular 
and interstitial cells may undergo senescence during glomerular 
diseases and hypertension.58 Therefore, different stressors that 
occur on different site may decide the localization and type of se-
nescent cells.
In the progression of kidney diseases, various types of cells, in-
cluding renal tubular epithelial cells, podocytes, endothelial cells, 
interstitial cells, immune cells and mesangial cells (Figure 2), may be-
come senescent and secrete a lot of factors, which are collectively 
named the CASP (CKD-associated secretory phenotype).57 SASP 
and CASP share many similarities, which might be the mediator of 
the crosstalk between cellular senescence and CKD.57
5.2 | Acute renal injury
Acute renal injury (AKI) is the primary driver of renal injury and CKD. 
AKI is characterized by a sudden deterioration of kidney function and 
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high morbidity and mortality. During AKI, the kidneys fail to elimi-
nate metabolic wastes, concentrate the urine and maintain water 
and electrolyte balance.60 Due to a rise in the elderly population, 
the incidence of AKI has significantly increased in recent years be-
cause age-related renal functional and morphological changes as 
well as accompanying comorbidities may promote the vulnerability 
of the elderly population to AKI.61 Increased susceptibility to injury 
and lack of sufficient repair in ageing and ischaemic kidneys may be 
associated with telomere shortening and other senescence-related 
mechanisms.62
Cell cycle arrest may serve as a protective mechanism follow-
ing AKI by allowing the cell to avoid the replication of damaged 
DNA. A study described that p21 knockout mice were more sus-
ceptible to ischaemia-induced acute renal failure.63 On the other 
hand, it has been shown that mitotic arrest at the G2/M phase 
plays a crucial role in response to AKI, where it drives maladaptive 
repair and progressive fibrosis; this suggests that renal recovery 
after injury would be hampered due to increased numbers of se-
nescent cells and reduced regenerative capacity of aged kidneys. 
Senescent tubular cells will reduce cell proliferation for repairing 
injury and contribute to the progression of renal fibrosis.64 A study 
demonstrated that sustained epithelial Notch activation may trig-
ger a pro-senescent state and maladaptive repair after ischaemia/
reperfusion damage, leading to more inferior outcome of old kid-
neys after injury.65 Therefore, the role of cell senescence in AKI is 
complex which needs to be elucidated in different time points of 
AKI or different models of AKI.
5.3 | Diabetic nephropathy
Diabetic nephropathy is a major cause of end-stage nephropathy. 
During the development of diabetic nephropathy, proteinuria is 
positively correlated with high-glucose-induced glomerular cell se-
nescence, which is related to the increased production of ROS.66 
A study demonstrated that proximal tubule epithelial cells (PTECs) 
are the major target for impaired glucose-induced metabolic disor-
ders.67 Also, Tsai et al confirmed that high glucose can induce the 
senescence of PTEC by increasing the expression of microRNA-378i, 
a potential biomarker of kidney damage in diabetic nephropathy.68 
Meanwhile, kidney interstitial injury is also critical to the develop-
ment of diabetic nephropathy.66
Increased p16 expression and SA-β-gal activity were observed 
in tubule cells, mesangial cells, podocytes and endothelial cells 
from patients with type 2 diabetic nephropathy59 and mice with 
streptozotocin-induced type 1 diabetes mellitus.69 Furthermore, 
several studies have demonstrated a direct link between hyper-
glycaemia and the induction of senescence in vitro in cultured 
proximal tubule cells69 and mesangial cells70 as well as in vivo in 
a mouse model of type 1 diabetes mellitus.69 Overall, these re-
sults indicate that hyperglycaemia is a crucial driver of cellular 
senescence, which may contribute to the progression of diabetic 
nephropathy.
5.4 | Glomerulonephritis
Recent studies show that cellular senescence is closely related to 
glomerular lesions and the degree of glomerular ageing is also re-
lated to the progression of nephropathy.58 For example, during 
IgA nephropathy (IgAN), disease progression is related to telomere 
shortening71 as well as several other senescence-related alterations 
such as elevated SA-β-gal activity and increased expression of p16 
and p21.72 These findings suggest that cellular senescence may play 
a crucial role in the development of IgAN. In this case, however, it 
remains to be clarified whether senescence is only associated with 
tissue damage or whether it promotes disease progression. Through 
a series of experiments and tests, Chen et al found that mice with 
lupus nephropathy (LN) and severe proteinuria showed enhanced 
SA-β-gal expression and administration of dexamethasone (DEX) 
reduced SA-β-gal expression and renal dysfunction, which sug-
gested that accelerated senescence of the glomerulus was related 
to the development of LN.73 Another study showed that bone mar-
row (BM)-derived mesenchymal stem cells (BM-MSCs) exhibited 
signs of senescence in systemic lupus erythematosus (SLE) pa-
tients and MRL/lpr mice. The senescent phenotype of BM-MSCs 
was involved in the pathogenesis of LN in MRL/lpr mice, which can 
be reversed by rapamycin.74 In addition, Chuang et al found that 
the reduction in podocyte SIRT1 led to senescence of podocytes 
along with reduced activation of peroxisome proliferator-activated 
receptor(PPAR)-a coactivator-1(PGC1a)/PPAR-γ, forkhead box O 
(FOXO)3, FOXO4 and p65 NF-κB, resulting in aggravated ageing-
induced glomerulosclerosis.75
5.5 | Renal fibrosis
Renal fibrosis is common in end-stage renal failure and may de-
velop from a variety of kidney diseases. Eventually, renal fibrosis 
leads to loss of kidney function. Recent studies indicate that the 
kidney with renal fibrosis is more prone to develop CKD due to 
incomplete recovery after AKI.76 Health regeneration or recovery 
after AKI should result in recovery of normal structure with differ-
entiated tubule epithelium. However, due to severe damage, recov-
ery of normal structure is often incomplete which contributes to 
the development of focal tubulointerstitial fibrosis.76 Renal fibro-
sis may be caused by the accelerated senescence of tubular cells; 
for example, Wnt9a induced senescent tubular cells to produce 
TGF-β1, driving proliferation and activation of rat kidney fibro-
blasts.77 In addition, TGF-β1 may induce premature senescence of 
mesangial cells and myofibroblast-like phenotype transformation, 
which may contribute to development of glomerulosclerosis.78 At 
the same time, it was reported that G2/M-arrested proximal tu-
bular cells activated c-jun NH(2)-terminal kinase (JNK) signalling, 
promoting pro-fibrotic cytokine production.79 The inactivation of 
p16 alleviated nephron atrophy and interstitial fibrosis in kidney 
transplant experiments.2 Therefore, senescent cells play a crucial 
part in the development of renal fibrosis.
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The role of cellular senescence in renal interstitial fibrosis ap-
pears to be complex. Senescent cells may contribute to pro-fibrotic 
circumstances through their SASP in ageing and kidney diseases.16 
But the specific role of cellular senescence in renal fibrosis has not 
yet been elucidated. Contrary to the general opinion about the det-
rimental effect of cellular senescence, there is evidence regarding a 
beneficial role of senescence in renal fibrosis. It has been reported 
that p16 inactivation promoted renal interstitial fibrosis in normal 
mice and a mouse model of unilateral ureteral occlusion.80 These 
seemingly contradictory findings demonstrated dual role of cellular 
senescence in different kidney injury processes. Further studies are 
needed to elucidate whether different effector molecules are in-
volved in the action of senescent renal tubular cells.
5.6 | Kidney transplantation
CKD as a trend in a variety of kidney diseases can lead to end-
stage renal disease (ESRD) if the renal function gradually deteri-
orates. In this case, kidney function deteriorates and alternative 
therapies such as a kidney transplant are necessary for patients 
with ESRD.81 Elderly patients are more susceptible to the com-
plications of kidney transplantation and the side effects of the 
immunosuppressive regimen, showing a lower survival rate after 
transplant.82 Cells from various tissue of the human body become 
senescent with age; therefore, ageing may also be one of the fac-
tors to affect the therapeutic effect of kidney transplantation. 
Other studies have demonstrated that ischaemia-reperfusion in-
jury during kidney transplantation causes oxidative stress, which 
in turn induces cellular senescence and accelerates dysfunction 
of the donor organ.83,84 In experimental rat models, kidney trans-
plant resulted in transient elevation of p21, sustained increase in 
p16, enhanced expression of SA-β-gal expression and accelerated 
telomere shortening.85 Furthermore, other studies showed that 
mice undergoing kidney transplant coupled with a loss of INK4a 
had a significantly better survival rate, less interstitial fibrosis and 
improved tubular cell proliferation, compared with mice that re-
ceived a wild-type transplant.2 Although kidney transplantation is 
the preferred treatment for ESRD,86 long-term failure of kidney 
transplants remains an important clinical problem. Long-term graft 
survival is affected by donor age. Ageing increases AKI and re-
duces renal regeneration capacity. Further, interstitial fibrosis and 
tubular atrophy were observed in ageing kidney graft. Therefore, 
kidney transplant senescence could promote graft loss. In addition, 
in human kidney transplant, CDKN2A expression in implantation 
biopsies was related to donor age and graft function.87 Telomere 
length assessed in biopsies collected in the peri-transplant period 
can predict the long-term kidney allograft function, and a signifi-
cant shortening of telomere was observed in patients with delayed 
graft function, acute rejection and chronic allograft dysfunction.88 
Therefore, all these findings demonstrated that senescence plays 
a crucial role in kidney transplantation, which may affect the out-
come and prognosis of kidney transplant.
5.7 | Polycystic kidney disease
The most common kind of polycystic kidney disease (PKD) is auto-
somal dominant polycystic kidney disease (ADPKD), which leads to 
ESRD in patients between 50 and 70 years.89 PKD belongs to the 
ciliopathies family and mainly influence the ciliated epithelial cells 
that line the renal tubules. PKD can also lead to tubule dilation 
by increasing cell proliferation.90 Reduced p21 levels in the kid-
ney are found in a rat model of PKD and patients with ADPKD.91 
Additionally, application of a CDK inhibitor, roscovitine, increases 
SA-β-gal activity, restores p21 expression, reduces proliferation 
of renal tubular cells and slows disease progression in an ADPKD 
mouse model.92 In contrast to aforementioned renal injury, these 
findings demonstrate that cellular senescence attenuates ADPKD 
progression.
6  | THER APEUTIC INTERVENTIONS 
FOR RENAL DISE A SES BY REGUL ATING 
SENESCENCE
Due to the important role of senescence and SASP in kidney dis-
ease, they have been proposed to be therapeutic targets for the 
treatment of these diseases. It has been verified that some drugs 
(including glucocorticoids, rapamycin and resveratrol) have ex-
tensive pharmacological effects in the management of renal dis-
eases. Notably, these drugs have been shown to reduce ROS levels 
and transcriptional activity of NF-κB, thereby decreasing cellular 
senescence.
For instance, rapamycin reduces transcription and translation of 
SASP factors, eventually resulting in secretome depletion through 
inhibition of mTOR and NF-κB transcriptional activity mediated by 
suppression of IL1A translation.13
Similar to the effects of rapamycin, pre-treatment with dexme-
detomidine also decreased the number of senescent tubular cells 
and weakened the protein expression of p53, p21 and p16,7 thus al-
leviating renal ischaemia/reperfusion-induced AKI and chronic renal 
fibrosis in later stages.
The important role of senescence in multiple diseases contrib-
utes to the exploration of novel treatments that can regulate se-
nescence. To overcome the detrimental effects of senescence on 
renal injury and ageing, the pharmacological effect of these novel 
treatments should focus on reducing the accumulation of senes-
cent cells or increasing the clearance of those cells. Anti-senescence 
compounds mainly include senolytics or senotherapeutics. Studies 
from animal experiments demonstrated that these compounds re-
versed ageing phenotypes and improved kidney function.93 ABT-
263(navitoclax), an inhibitor of Bcl-2 family, has been confirmed as a 
senolytic, showing to remove senescent cells in aged mice and allow 
for tissue regeneration.94 However, the side effect of navitoclax lies 
in apoptosis and is not restricted to cellular senescence. Other BCL-2 
family inhibitors such as A1331852 and A1155463 were manifested 
to be toxic and did not target all senescent cells.95 Therefore, the 
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benefit of removing senescent cells has not been completely clari-
fied by these experiments. Feasibility of this treatment for each kid-
ney disease should also be evaluated.
Kidney transplantation may be a suitable scenario for the appli-
cation of senolysis. Anti-senescent treatments should focus on the 
removal of sustained senescent cells but not on preventing the in-
duction of a temporary cell cycle arrest at the early stage of kidney 
transplantation. The anti-senescence compound FOXO4-DRI has 
proven to be potent for therapy of the ageing kidney. In senescent 
cells, FOXO4 was observed to serve as a binding partner of p53, 
preventing these cells from p53-induced pro-apoptotic response. 
Therefore, FOXO4-DRI can interrupt FOXO4-p53 interaction and 
contribute to p53-induced apoptosis of senescent cells.96
In addition, chronic treatment of the senolytic drug quercetin 
alleviated the expression of p16, p19 and p53, reducing renal fibro-
sis induced by obesity and dyslipidaemia.97 Interestingly, Leung et 
al found that the treatment of YAP inhibitor verteporfin inhibited 
activation of senescence-associated genes, SASPs and activation of 
Stat3 as well as impeded the development of tubulointerstitial fi-
brosis.98 Furthermore, erythropoietin can preserve tubular epithe-
lial cell regeneration and reduce renal fibrosis in mice with unilateral 
ureteral obstruction by inhibiting SIPS and epithelial-to-mesenchy-
mal transition of renal epithelial cells.99
For diabetic nephropathy, it has been shown that rapamycin or 
resveratrol inhibits mesangial cells (MCs) senescence induced by 
high glucose through increasing the SIRT1 expression and activity, 
which was completely blocked by treatment with siRNA-SIRT1.100
In addition, as mentioned, in an experimental LN study, intra-
gastric administration of rapamycin alleviated symptoms of LN by 
reversing the senescence of BM-MSCs in MRL/lpr mice through in-
hibition of the mTOR signalling pathway.74 Also, CDK inhibitors such 
as roscovitine may be a therapeutic approach for the treatment of 
PKD.92
7  | SUMMARY/FUTURE PERSPEC TIVES
Overall, cellular senescence and SASP are involved in kidney injury 
during both degenerative and hyperplastic diseases. In many renal 
diseases and in the ageing kidney, there is an accumulation of G1- 
and G2-arrested senescent cells in multiple regions within the kid-
ney, especially in the renal tubular cells of the cortex. Thus, renal 
function in failing or ageing kidneys may be improved by targeting 
senescent cells or SASP.
During the development of renal disease, senescence plays a 
time-dependent role in the progression of renal fibrosis, which is 
beneficial in the early stage but detrimental in the late stage with 
long-term adverse consequences. Therefore, it is important to un-
derstand how cellular senescence plays a protective or a detrimental 
effect during different periods of renal injury and the mechanisms 
of senescence underlying the progression of CKD such as renal fi-
brosis. Further research is needed to clarify the characteristics of 
all senescent cells and the specific targets of senescent cells in renal 
diseases. Until now, most findings were acquired through studying 
animal models; therefore, the role of senescence in human renal dis-
eases should be validated in future studies. Additionally, novel strat-
egies to inhibit the progression of CKD by removing senescent cells 
in vivo, including targeted gene therapy to avoid side effects in other 
organs, need further exploration.
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